WO2012108855A1 - A two-stage system and method for oxygenating and removing carbon dioxide from a physiological fluid - Google Patents
A two-stage system and method for oxygenating and removing carbon dioxide from a physiological fluid Download PDFInfo
- Publication number
- WO2012108855A1 WO2012108855A1 PCT/US2011/000236 US2011000236W WO2012108855A1 WO 2012108855 A1 WO2012108855 A1 WO 2012108855A1 US 2011000236 W US2011000236 W US 2011000236W WO 2012108855 A1 WO2012108855 A1 WO 2012108855A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxygen
- carbon dioxide
- carrier fluid
- fluid
- exchange module
- Prior art date
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 275
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 title claims abstract description 254
- 229910002092 carbon dioxide Inorganic materials 0.000 title claims abstract description 127
- 239000001569 carbon dioxide Substances 0.000 title claims abstract description 127
- 230000001706 oxygenating effect Effects 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 148
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 148
- 239000001301 oxygen Substances 0.000 claims abstract description 148
- 239000007789 gas Substances 0.000 claims abstract description 72
- 238000012546 transfer Methods 0.000 claims abstract description 61
- 239000012510 hollow fiber Substances 0.000 claims description 33
- 210000004072 lung Anatomy 0.000 claims description 29
- 238000004891 communication Methods 0.000 claims description 19
- 230000002792 vascular Effects 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 11
- 239000000835 fiber Substances 0.000 claims description 10
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 239000012080 ambient air Substances 0.000 claims description 3
- 239000000560 biocompatible material Substances 0.000 claims description 3
- 229910001882 dioxygen Inorganic materials 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 241000237509 Patinopecten sp. Species 0.000 claims description 2
- 235000020637 scallop Nutrition 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 238000009792 diffusion process Methods 0.000 description 16
- 102000029749 Microtubule Human genes 0.000 description 14
- 108091022875 Microtubule Proteins 0.000 description 14
- 210000004688 microtubule Anatomy 0.000 description 14
- 238000002054 transplantation Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 6
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 6
- 238000003491 array Methods 0.000 description 5
- 0 CCCCC*1C#CC(C)CC1 Chemical compound CCCCC*1C#CC(C)CC1 0.000 description 4
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002689 xenotransplantation Methods 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- -1 polytetra- fluoroethylene Polymers 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000004193 respiratory failure Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- UAEPNZWRGJTJPN-UHFFFAOYSA-N CC1CCCCC1 Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004697 Polyetherimide Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229940058401 polytetrafluoroethylene Drugs 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1698—Blood oxygenators with or without heat-exchangers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/32—Oxygenators without membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
- B01D63/028—Microfluidic devices comprising semi-permeable hollow fibre membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1678—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes intracorporal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0244—Micromachined materials, e.g. made from silicon wafers, microelectromechanical systems [MEMS] or comprising nanotechnology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/04—General characteristics of the apparatus implanted
Definitions
- This invention relates to a two-stage system and method for oxygenating and removing carbon dioxide from a physiological fluid.
- lungs The main function of lungs is to transfer oxygen from the atmosphere into the blood and expel carbon dioxide therefrom to the atmosphere.
- Some of the most common diseases leading to end-stage lung failure include, inter alia, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), and pulmonary hypertension (PH).
- COPD chronic obstructive pulmonary disease
- CF cystic fibrosis
- IPF idiopathic pulmonary fibrosis
- PH pulmonary hypertension
- COPD chronic obstructive pulmonary disease
- CF cystic fibrosis
- IPF idiopathic pulmonary fibrosis
- PH pulmonary hypertension
- Cardiopulmonary bypass is a technique used to take over the function of the heart and lungs during surgery by regulating the circulation of blood and oxygen within a person's body.
- the artificial lung may provide short-term pulmonary support during extensive operations on the heart.
- ARDS acute respiratory distress syndrome
- Conventional systems have also been developed for short-term pulmonary support (e.g., days to a few weeks). These systems include extracorporeal membrane oxygenation (ECMO) devices, extracorporeal carbon dioxide removal (ECC0 2 R) devices, and intravascular oxygenators ( ⁇ ) devices.
- ECMO extracorporeal membrane oxygenation
- ECC0 2 R extracorporeal carbon dioxide removal
- ⁇ intravascular oxygenators
- ECC0 2 R and ECMO are also one-stage systems and may be limited by the inclusion of fibers that come in contact with blood thereby causing blood activation and
- IVOX systems have been the primary focus for treating diseased or damaged lung(s).
- Conventional one-stage IVOX systems typically include membranous or fibrous components used for oxygenation.
- a bundle of hollow fibers may be used as the oxygenating element. Exposing blood to the large artificial surface area needed for gas exchange often causes blood activation and thrombogenesis.
- This invention features a two-stage system for oxygenating and removing carbon dioxide from a physiological fluid, the system including a primary exchange module configured to receive a gas having oxygen therein and an carrier fluid having carbon dioxide therein.
- the primary exchange module is configured to transfer oxygen from the gas to the carrier fluid and transfer carbon dioxide from the carrier fluid to the gas to create an oxygen loaded carrier fluid and a carbon dioxide load gas, and a secondary exchange module is configured to receive the oxygen loaded carrier fluid and a physiological fluid having the carbon dioxide therein.
- the secondary exchange module configured to transfer the oxygen from the oxygen loaded carrier fluid to the
- physiological fluid and transfer carbon dioxide from the physiological fluid to the carrier fluid to create an oxygen loaded physiological fluid.
- the primary exchange module may include a gas and fluidic distribution subsystem including one or more of: a gas inlet configured to receive the gas having the oxygen therein, a fluidic inlet in fluidic communication with the secondary exchange module configured to receive the carrier fluid having carbon dioxide therein, a fluidic outlet in fluidic communication with the secondary exchange module configured to transfer the oxygen loaded carrier fluid to the secondary exchange module, and a gas outlet configured to expel the carbon dioxide loaded gas from the primary exchange module.
- the gas having the oxygen therein gas may include one or more of: ambient air, oxygen gas, and a gas containing oxygen.
- the secondary exchange module may include a fluidic distribution subsystem including one or more of: a first fluidic inlet in fluidic communication with the primary exchange module configured to receive the oxygen loaded carrier fluid, a second fluidic inlet in fluidic communication with the physiological fluid having the carbon dioxide therein, a first fluidic outlet in fluidic communication with the primary exchange module configured to transfer the carrier fluid having carbon dioxide therein to the primary exchange module, and a second fluidic outlet configured to transfer the oxygen loaded physiological fluid to the vascular system of the patient.
- the second fluidic inlet and/or the second fluidic outlet may be coupled to the vascular systems of a patient.
- the primary exchange module may include at least one array having plurality of hollow fibers configured to receive the gas having the oxygen therein and in fluidic communication with the carrier fluid having carbon dioxide therein.
- the at least one array configured to provide the transfer of the oxygen from the gas to the carrier fluid and the transfer of the carbon dioxide from the carrier fluid to the gas.
- the distance between one or more and/or each of the plurality of hollow fibers may be configured to provide the transfer of oxygen and said transfer of carbon dioxide.
- the plurality of fibers may be configured such that the distance between one or more and/or each of the plurality of fibers is smaller than or equal to the outer diameter of one or more and/or each of the plurality of fibers.
- the at least one array may include a plurality of headers configured to align the plurality of hollow fibers in a predetermined orientation.
- the secondary exchange module may include at least one microfluidic channel in fluidic communication with the oxygen loaded carrier fluid and the physiological fluid having carbon dioxide therein configured to create a parallel flow of the oxygen loaded carrier fluid and the physiological fluid having carbon dioxide therein to provide said transfer of oxygen and said transfer of carbon dioxide.
- the at least one microfluidic channel may be configured with a predetermined height to create the parallel flow.
- the at least one microfludic channel may be configured with a predetermined height to reduce the Reynolds number such that the effective viscosity of the oxygen loaded carrier fluid and the physiological fluid is increased to maintain said parallel flow.
- the predetermined height may be less than or equal to about 1 mm.
- the at least one microfludic channel may include at least two opposing surfaces.
- the opposing surfaces may be coated with and/or made of a material configured to stabilize and further separate said parallel flow.
- One of the opposing surfaces may be coated with and/or made of a material having hydrophilic properties configured to attract the physiological fluid and repel the oxygen loaded carrier fluid to stabilize and further separate said parallel flow.
- One of the opposing surfaces may be coated with and/or made of a material having hydrophobic properties configured to attract the oxygen loaded carrier fluid and repel the physiological fluid to stabilize and further separate said parallel flow.
- the carrier fluid and the physiological fluid may be configured to be immiscible with each other to stabilize and further separate said parallel flow.
- the at least one microfludic channel may include a predetermined shape configured to increase the surface area of the microfludic channel in relation to the cross- sectional area of the microfludic channel to stabilize and separate said parallel flow.
- the predetermined shape may include one or more of: a rectangular shape, a circular shape, an offset circular shape, and a scallop shape.
- the at least one microfludic channel may be made of bio-compatible material.
- the at least one microfludic channel may be housed in a chamber.
- the at least one microfludic channel may include a plurality of microfludic channels.
- the carrier fluid may include plerfluorocarbon.
- the primary exchange module may include a blower and/or plurality of bellows configured to deliver the gas having oxygen therein thereto.
- the primary exchange module and the secondary exchange module may be located external from the patient.
- the primary exchange module and the secondary exchange module may be implanted within a patient.
- the primary exchange module and the secondary exchange module may be configured in the shape of a lung.
- the lung may be implanted within a patient.
- This invention also features a two-stage method for oxygenating and removing carbon dioxide from a physiological fluid, the method including providing a first stage configured to receive a gas having oxygen therein, receive an carrier fluid having carbon dioxide, and transfer oxygen from the gas to the carrier fluid and transfer carbon dioxide from the carrier fluid to the gas to create an oxygen loaded carrier fluid and a carbon dioxide loaded gas.
- a second stage is configured to receive the oxygen loaded carrier fluid, receive a physiological fluid having the carbon dioxide therein, and transfer the oxygen from the oxygen loaded carrier fluid to the physiological fluid and transfer carbon dioxide from the physiological fluid to the carrier fluid to create an oxygen loaded physiological fluid.
- receiving the physiological fluid may include receiving a physiological fluid from the vascular system of a patient.
- the method may include the step of transferring the oxygen loaded physiological fluid to the vascular system of a patient.
- the method may include the step of creating a parallel flow of the oxygen loaded carrier fluid and the physiological fluid having carbon dioxide therein to provide the transfer of the oxygen from the oxygen loaded carrier fluid to the physiological fluid and the transfer of the carbon dioxide from the physiological fluid to the carrier fluid.
- the method may include the step of stabilizing and further separating said parallel flow.
- the method may include the step of increasing the effective viscosity of the oxygen loaded carrier fluid and the physiological fluid to maintain said parallel flow.
- Fig. 1 is a block diagram showing the primary components of one embodiment of the two-stage system for oxygenating and removing carbon dioxide from a physiological fluid of this invention
- Fig. 2 is a three-dimensional view showing in further detail the primary exchange module shown in Fig. 1 ;
- Fig. 3 A is a three-dimensional view showing in further detail one example of the flow of the carrier fluid having carbon dioxide between hollow fibers shown in Fig. 2;
- Fig. 3B is a schematic end-view showing the flow of the carrier fluid having carbon dioxide between hollow fibers shown in Fig. 2;
- Fig. 4 is a schematic end-view showing in further detail one embodiment of the structure of the plurality of hollow fibers shown in Figs. 2-3B;
- Fig. 5 is a schematic end-view showing one example of headers used to align the hollow fibers shown in Figs. 2-3B in a predetermined orientation;
- Fig. 6A is a schematic end-view showing one example of the structure of the microfluidic channel of the secondary exchange module shown in Fig. 1 ;
- Fig. 6B is a schematic top-view of the micro fluidic channel shown in Fig. 6A showing one example of oxygen loaded carrier fluid traveling over physiological fluid having carbon dioxide therein;
- Fig. 6C is a schematic bottom- view of the microfluidic channel shown in Fig. 6 showing one example of the physiological fluid having carbon dioxide therein traveling under the oxygen loaded carrier fluid;
- Fig. 7 is a three-dimensional front-view showing in further detail one embodiment of the microfluidic channels shown in Fig. 6A-C;
- Fig. 8A is a schematic end-view showing one example of the shape of one or more of the microfluidic channels shown in Fig. 6A-7;
- Fig. 8B is a schematic front-view showing another example of the shape of one or more of the microfluidic channels shown in Fig. 6A-7;
- Fig. 8C is a schematic front- view of yet another embodiment of the microfluidic channel shown in Fig. 6A-7;
- Fig. 8D is a schematic front-view of yet another embodiment of the microfluidic channel shown in Fig. 6A-7;
- Fig. 9 is a schematic front-view showing one example of the operation of the two- stage system for oxygenating and removing carbon dioxide from a physiological fluid of this invention.
- Fig. 10 is a schematic front- view of the system shown in Fig. 9 wherein the blower has been replaced with bellows;
- Fig. 1 1 is a three-dimensional side-view showing one example of the primary exchange module and the secondary exchange module shaped as a lung;
- Fig. 12 is a three-dimensional front-view showing one example of the two-stage system of this invention located outside the body of a patient;
- Fig. 13 is a three-dimensional front-view showing one example of the two-stage system of this invention implanted within the abdomen of a patient;
- Fig. 14 is a three-dimensional view showing one example of the two-stage system of this invention shaped as a lung and implanted within a patient.
- System 10 includes primary exchange module 12 configured to receive gas 14 having oxygen therein and carrier fluid 16 having carbon dioxide therein.
- the gas having oxygen therein may include ambient air, an oxygen gas, or any gas having oxygen therein.
- Carrier fluid 16 is preferably immiscible with respect to physiological fluid 22 and may be made of a perfluorocarbon, such as a perfluorodecalin (Ci 0 Fi 8 ), or similar type compound known to those skilled in the art, that prevents carrier fluid 16 from mixing with physiological fluid 22 having carbon dioxide therein (discussed below).
- Primary exchange module 12 transfers oxygen from gas 14 having oxygen therein to carrier fluid 16 and transfers the carbon dioxide in carrier fluid 16 to gas 14 to create oxygen loaded carrier fluid 18 and carbon dioxide loaded gas 20. Carbon dioxide loaded gas is preferably expelled from primary exchange module 12, as shown at 21.
- System 10 also includes secondary exchange module 20 which receives oxygen loaded carrier fluid 18 from primary exchange module 12, indicated at 19, and physiological fluid 22 having carbon dioxide therein indicated at 23.
- Physiological fluid 22 may include blood, serum, or any similar type physiological fluid having carbon dioxide therein.
- physiological fluid 22 having carbon dioxide therein may be received from vascular system of a patient 120.
- Secondary exchange module transfers the oxygen from oxygen loaded carrier fluid 18 to physiological fluid 22 and transfers carbon dioxide from physiological fluid 22 to produce oxygen loaded physiological fluid 24 and carrier fluid 16 having carbon dioxide therein.
- Oxygen loaded physiological fluid 24, which now has carbon dioxide removed, may then be transferred to vascular system of a patient 120, as shown at 121.
- Carrier fluid 16, having carbon dioxide therein is transferred to primary exchange module 12, as shown at 130.
- system 10 receives physiological fluid 22 having carbon dioxide therein, effectively removes carbon dioxide therefrom and loads physiological fluid 22 with oxygen. Oxygen loaded physiological fluid 24 may be then transferred to vascular system of patient 120.
- system 10 can be used to effectively assist or replace the function of diseased or damaged lung(s) discussed in the Background section above.
- system 10 may be used as an artificial lung. Because system 10 is a two-stage system, the problems discussed above with conventional systems, such as ECMO and IVOX, and the like, may be significantly reduced or eliminated.
- Primary exchange module 12 preferably includes at least one array, e.g., array 25, Fig. 2, which includes a plurality of hollow fibers 26 which receives gas 14 having oxygen therein.
- gas 14 enters hollow fibers 26 in the direction indicated by arrow 15 and flows through hollow fibers 26.
- Array 25 is preferably in fluidic communication with carrier fluid 16 having carbon dioxide therein.
- carrier fluid 16 having carbon dioxide flows into array 25, in the direction indicated by arrows 17 and travels about and in close proximity to each of the hollow fibers 26, e.g., as indicated by arrows 38, 40, 42, 44, 46, and 48, Figs. 3 A 48 (discussed below).
- Hollow fibers 26 efficiently transfer the oxygen in gas 14 to the carrier fluid 16 and efficiently transfer the carbon dioxide in carrier fluid 16 to the gas inside hollow fibers 26.
- Fig. 3 A shows one embodiment of primary exchange module 12 including a plurality of arrays, e.g., arrays 25, 27, 29, 31, 35. Each of arrays 25-35 similarly includes hollow fibers 26 as discussed above.
- carrier fluid 16 having carbon dioxide therein enters primary exchange module 12 by line 30 and then flows in between and the arrays as shown by arrows 32, 34, and 34. Carrier fluid 16 then travels in an upward and downward direction and flows in between and about hollow fibers 26 of arrays 25-35, indicated by arrows 38, 40, 42, 44, 46, and 48.
- carrier fluid 16 travels in between, about, and in close proximity to, hollow fibers 26, hollow fibers 26 efficiently transfer the oxygen in gas 14, Figs.
- Fig. 3B is an end view array 25 of primary exchange module 12 and shows another example of the flow of carrier fluid 16 around, about, and in close proximity to hollow fibers 26 of array 25.
- the distance between one or more, or each of, hollow fibers 26, Figs. 2-3B is preferably configured to provide the efficient transfer of the oxygen from the gas having oxygen therein to the carrier fluid and the transfer of the carbon dioxide from the carrier fluid to the gas as discussed above.
- the distance between one or more, or of each hollow fiber 26 is preferably smaller than or equal to the outer diameter hollow fibers 26.
- distance d-40, Fig. 4 between hollow fiber 42 and hollow fiber 44 of the plurality of hollow fibers 26 is preferably smaller than or equal the outer diameter d-48 of fiber 42 and outer diameter d-50 of fiber 44.
- the distance d-40 is about 100 microns and outer diameter distances d-48 and d- 50 are about 125 microns.
- array 25, Fig. 2 preferably includes headers 60, Fig. 5, which align hollow fibers 26 in a closely packed configuration as shown in Figs 2-3B. Header 60 also preferably align hollow fibers 26 of the array(s) such that the distance between one or more of each of the hollow fibers 26 is smaller than or equal to the outer diameter of each of the plurality of fibers, as discussed above with reference to Fig. 4.
- Secondary exchange module 20, Fig. 1 preferably includes at least one microfluidic channel 70, Fig. 6A, which is designed to create a parallel flow of oxygen loaded carrier fluid 18 and physiological fluid 22 having carbon dioxide therein.
- the parallel flow of oxygen loaded carrier fluid 18 and physiological fluid 22 having carbon dioxide therein provides the efficient transfer of oxygen and carbon dioxide between carrier fluid 18 and physiological fluid 22 to create oxygen loaded physiological fluid 22, and carrier fluid 16 having carbon dioxide therein, Fig. 1, as discussed above.
- channel 70, Fig. 6A is preferably designed with a predetermined height to create the parallel flow of oxygen loaded carrier fluid 18 and physiological fluid 22 having carbon dioxide therein.
- the predetermined height is less than or equal to about 1 mm.
- the height of channel 70 may also be designed to reduce the Reynolds number such that the effective viscosity of oxygen loaded carrier fluid 18 and physiological fluid 22 is increased to maintain the parallel flow.
- the length of channel 70 is preferably long enough such that the parallel flow of oxygen loaded carrier fluid 18 and physiological fluid 22 having carbon dioxide provides for efficiently transferring the oxygen and carbon dioxide as discussed above. In one example, length of channel 70 is about 0.5 mm to about 2.5 cm, although channel 70 may be any length as known by those skilled in the art.
- Fig. 6B shows a top view of one example of flow 72 of oxygen loaded carrier fluid 18 in parallel and flowing over physiological fluid 22 having carbon dioxide therein.
- Fig. 6C shows an example of a bottom view of channel 70 depicting flow 74 of physiological fluid 22 flowing parallel to and, in this example, under oxygen loaded carrier fluid 18. In other examples physiological fluid 22 may flow in parallel and over oxygen loaded carrier fluid 18.
- secondary gas exchange module 20, Fig. 1 includes a plurality of channels, e.g., channels 70, 80, and 82, Fig. 6A.
- channel 70 creates a parallel flow of oxygen loaded carrier fluid 18 and physiological fluid 22 having carbon dioxide therein, as discussed above.
- channel 80 creates a parallel flow of oxygen loaded carrier fluid 18 and physiological fluid 22 having carbon dioxide therein
- channel 82 creates a parallel flow of oxygen loaded carrier fluid 18 and physiological fluid 22 having carbon dioxide therein.
- the plurality of channel 70, 80, and 82 are housed in chamber 86.
- oxygen loaded carrier fluid 18 flows into microtubule 86, enters channel 70 at inlet plenum 88, and then flows in the direction shown by arrows 90 to the far end of channel 70 where it exits channel 70 as carrier fluid 16 having carbon dioxide therein via outlet plenum 92.
- Carrier fluid 16 having carbon dioxide therein then flows into microtubule 96, travels down microtubule 96, and then exits secondary exchange module 20 via outlet 97.
- Carrier 16 having carbon dioxide therein is then transferred to primary exchange module 12, Fig. 1 and processed as discussed above.
- Oxygen loaded physiological fluid 24 then flows into microtubule 108, travels down microtubule 108, and then exits secondary exchange module 20 via outlet 1 1 0.
- Oxygen loaded physiological fluid 22 may then be transferred back to vascular system of a patient 120, Fig. 1.
- oxygen loaded carrier fluid 18, Fig. 7 may flow into microtubule 86, enter channels 80, 82 at inlet plenums 140, 160, respectively, and then flows in the direction shown by arrows 148, 164 to the far end of channels 80, 82 where it exits channels 80, 82 as carrier fluid 16 having carbon dioxide therein via outlet plenums 150, 166, respectively.
- Carrier fluid 16 having carbon dioxide therein then flows into microtubule 96, travels down microtubule 96, and exits secondary exchange module 20 via outlet 97.
- Carrier 16 having carbon dioxide therein may be then transferred to primary exchange module 12, Fig. 1 where it is processed as discussed above.
- Physiological fluid 22 having carbon dioxide therein flows into microtubule 100, Fig. 7, enters channels 80, 82 via inlet plenums 152, 170, respectively, travels in the direction indicated by arrows 154, 172 to the far end of channels 80, 82 where it exits channels 80, 82 as oxygen loaded physiological fluid 22 via a outlet plenums 156, 176, respectively.
- Oxygen loaded physiological fluid 24 then flows into microtubule 108, travels down microtubule 108, and then exits secondary exchange module 20 via outlet 110.
- Oxygen loaded physiological fluid 22 may then be transferred back to vascular system of a patient 20, Fig. 1.
- microfludic channels 70, 80, and/or 82 create a parallel flow of oxygen loaded carrier fluid 18 and physiological fluid 22 having carbon dioxide therein.
- the parallel flow provides an efficient transfer of oxygen from oxygen loaded carrier fluid 18 to physiological fluid 22 having carbon dioxide therein and an efficient transfer of the carbon dioxide from physiological fluid 22 to the carrier fluid 16 to create oxygen loaded physiological fluid 22 and carrier fluid 16 having carbon dioxide therein.
- oxygen-loaded physiological fluid 22 has the carbon dioxide removed therefrom. Oxygen loaded physiological fluid 22 may then be transferred to vascular system of a patient 120, Fig. 1, and carrier fluid 16 having carbon dioxide therein is transferred to primary exchange module 12, as discussed above.
- microfluidic channel 70, Figs. 6A, and 7, and/or microfludic channels 80 and 82 may include opposing surfaces which may be coated with, or made of, a material configured to stabilize and further separate the parallel flow of oxygen loaded carrier fluid 18 and physiological fluid 22 having carbon dioxide therein.
- opposing surfaces 180, 182, e.g. surface 180, Fig. 6A may be coated, or made of, a material having hydrophobic properties which attract oxygen loaded carrier fluid 18 and repel physiological fluid 22.
- the other of surfaces 180, 182, e.g., surface 182 may be coated with, or made of, a material having hydrophylic properties which attract physiological fluid 22 having carbon dioxide therein and repel the oxygen loaded carrier fluid 18.
- surface 180 is coated with, or made of a fluorinated compound, such as polytetra- fluoroethylene and surface 182 is coated with, or made of polyhydroxyethylmethacrylate.
- Surfaces 180 and 182 may be coated with, or made of, or similar type materials known to those skilled in art.
- carrier fluid 18 and physiological fluid 22 are immiscible with each other to stabilize and further separate the parallel flow thereof.
- Microfluidic channel 70, Figs. 6A-7, with opposing surfaces 180, 182 and/or microfluidic channels 80, 82 (which similarly have opposing surfaces) preferably includes a predetermined shape which increases the surface area thereof in relation to the cross- sectional area of the microfluidic channel to stabilize and further separate the parallel flow of carrier fluid 18 and physiological fluid 22.
- channel 70 and/or channels 82, 82 may have a scalloped shape as shown in Fig. 8A, a circular shape as shown in Fig. 8B, an offset circular shape as shown in Fig. 8C, or a rectangular shape as shown in Fig. 8D.
- Other shapes that increase surface area relative to cross-sectional area will be known to those skilled in the art.
- microfluidic channel 70 and/or microfluidic channels 80, 82 are made of a bio-compatible material, such as polycarbonate, polyetherimide or similar type materials.
- carrier fluid 16 having carbon dioxide therein and/or oxygen loaded carrier fluid 18 may include a plerfluro carbon that prevents carrier fluid 16 from mixing with physiological fluid 22 having carbon dioxide therein
- Fig. 9 shows one embodiment of system 10 which is shaped similar to the shape of a human lung.
- primary exchange module 12 includes gas and fluidic distribution subsystem 200 which may include gas inlet and line 202 coupled to array 25 having hollow fibers 26 as discussed above with reference to Figs 2-4.
- subsystem 200, Fig. 9, may include blower 204, or similar type device, which draws gas 14 have oxygen therein and delivers it to array 25.
- bellows 290, Fig. 10, where like parts have been given like numbers may be used.
- Subsystem 200, Fig. 9, also includes inlet 206 which is in fluidic communication with secondary exchange module 20. Inlet 206 receives a flow of carrier fluid 16 having carbon dioxide therein from secondary exchange module 22.
- Gas and fluidic distribution subsystem 200 also preferably includes fluidic outlet 210 which transfers oxygen loaded carrier fluid 18 via microtubule 212 to microfluidic channels 70, 80, 82, and 84 of secondary exchange module 22, similar as discussed above with reference to Figs. 6A-7.
- Gas and fluidic distribution subsystem 200 also includes gas outlet 221 which expels carbon dioxide loaded gas 20 to the environment.
- Secondary exchange module 20 preferably includes fluidic inlet 220 which receives physiological fluid 22 having carbon dioxide therein. Inlet 220 is in fluidic communication via microtubule 222 to each of channels 70, 80, 82, and 84.
- Microfluidic channels 70, 80, 82, and 84 create a parallel flow of physiological fluid 22 having carbon dioxide therein and oxygen loaded carrier fluid 18, similar as discussed above with reference to Figs. 6A-7, to provide the efficient transfer of oxygen from the oxygen loaded carrier fluid 18 to physiological fluid 22 and the transfer of carbon dioxide from physiological fluid 22 to the carrier fluid 18 to create oxygen loaded physiological fluid 24.
- Secondary exchange module 20 preferably includes outlet 230 in fluidic communication with channels 70, 80, 82, and 84.
- Outlet 250 is preferably coupled to a vascular system of a patient 120, Fig. 1 to deliver oxygen loaded physiological fluid 24 to vascular system of the patient 120.
- Secondary exchange module 22 also includes fluidic outlet 211 in fluidic communication with inlet 206 of primary exchange module 12 which transfers carrier fluid 16 having carbon dioxide therein to primary exchange module 12.
- pump 270 may be used to drive the transfer of carrier fluid 16 having carbon dioxide therein to primary exchange module 12.
- system 10 with primary exchange module 12 and secondary exchange module 20 may be configured in the shape of a lung as shown in Fig. 1 1.
- system 10 may be located outside the body of patient 300, Fig. 12, and connected to patient 300 by catheter 302.
- system 10, Fig. 13, may be implanted within abdomen 308 of patient 300.
- system 10 may be in the shape of a lung and implanted into patient 300 as shown in Fig. 14.
- Equation (1) can be applied to the diffusion process by considering the flow in the channel to consist of contacting slugs of physiological fluid, e.g., blood, and carrier fluid that move through the channel in unison. The time over which diffusion occurs between the two slugs is the time it takes them to pass through the channel. With these assumptions and after significant algebraic manipulation, Equation (1) can be
- L is the diffusion channel length in mm
- a is the diffusion channel length relative to width W, i.e., its aspect ratio L/W
- b is the physiological fluid sheet thickness in mm
- n is the number of diffusion channels connected in parallel
- D is the diffusion coefficient of oxygen in physiological fluid.
- the diffusion coefficient is used for oxygen since it is the limiting factor over the far higher diffusion coefficient of carbon dioxide.
- Equation (2) Equation (2)
- Equation 5 Equation 5 reduces to: nb
- Equations (3) and (6) the length of the diffusion channel is proportional to the square root of the blood sheet height b, while the channel pressure drop is inversely proportional to b 3 .
- the corresponding diffusion channel length and pressure drop given by Equations (3) and (6) are:
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2011/000236 WO2012108855A1 (en) | 2011-02-10 | 2011-02-10 | A two-stage system and method for oxygenating and removing carbon dioxide from a physiological fluid |
EP11858232.9A EP2673039A4 (de) | 2011-02-10 | 2011-02-10 | Zweistufiges system und verfahren zur sauerstoffanreicherung und entfernung von kohlendioxid aus einer physiologischen flüssigkeit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2011/000236 WO2012108855A1 (en) | 2011-02-10 | 2011-02-10 | A two-stage system and method for oxygenating and removing carbon dioxide from a physiological fluid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012108855A1 true WO2012108855A1 (en) | 2012-08-16 |
Family
ID=46638854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/000236 WO2012108855A1 (en) | 2011-02-10 | 2011-02-10 | A two-stage system and method for oxygenating and removing carbon dioxide from a physiological fluid |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2673039A4 (de) |
WO (1) | WO2012108855A1 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019079838A1 (en) * | 2017-10-25 | 2019-05-02 | Technische Universität Wien | METHOD AND SYSTEM FOR REGULATING PERMEAT EXCHANGE RATES |
CN111494741A (zh) * | 2020-05-25 | 2020-08-07 | 清华大学 | 一种用于体外循环的人工肺 |
US11191888B1 (en) | 2020-05-18 | 2021-12-07 | Agitated Solutions Inc. | Syringe-based microbubble generator |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492109A (en) * | 1993-11-03 | 1996-02-20 | The Regents Of The University Of Michigan | Liquid ventilator with venturi-inducing patient connector |
EP0934751A1 (de) | 1998-02-05 | 1999-08-11 | Institut für Polymerforschung Dresden e.V. | Verfahren und Vorrichtung zur Oxygenation von Blut |
US20020143397A1 (en) * | 2001-04-02 | 2002-10-03 | Von Segesser Ludwig K. | Compliant artificial lung for extrapulmonary gas transfer |
US20040009096A1 (en) * | 2002-06-08 | 2004-01-15 | Wellman Parris S. | Substantially inertia free hemodialysis |
US20090018484A1 (en) * | 2007-07-11 | 2009-01-15 | Levitov Alexander B | System device and method for oxygenation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4665791B2 (ja) * | 2005-04-15 | 2011-04-06 | ニプロ株式会社 | 酸素運搬体の脱一酸化炭素化方法、脱一酸化炭素化された酸素運搬体、その医薬組成物及び脱一酸化炭素化装置 |
-
2011
- 2011-02-10 WO PCT/US2011/000236 patent/WO2012108855A1/en active Application Filing
- 2011-02-10 EP EP11858232.9A patent/EP2673039A4/de active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492109A (en) * | 1993-11-03 | 1996-02-20 | The Regents Of The University Of Michigan | Liquid ventilator with venturi-inducing patient connector |
EP0934751A1 (de) | 1998-02-05 | 1999-08-11 | Institut für Polymerforschung Dresden e.V. | Verfahren und Vorrichtung zur Oxygenation von Blut |
US20020143397A1 (en) * | 2001-04-02 | 2002-10-03 | Von Segesser Ludwig K. | Compliant artificial lung for extrapulmonary gas transfer |
US20040009096A1 (en) * | 2002-06-08 | 2004-01-15 | Wellman Parris S. | Substantially inertia free hemodialysis |
US20090018484A1 (en) * | 2007-07-11 | 2009-01-15 | Levitov Alexander B | System device and method for oxygenation |
Non-Patent Citations (1)
Title |
---|
See also references of EP2673039A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019079838A1 (en) * | 2017-10-25 | 2019-05-02 | Technische Universität Wien | METHOD AND SYSTEM FOR REGULATING PERMEAT EXCHANGE RATES |
US11191888B1 (en) | 2020-05-18 | 2021-12-07 | Agitated Solutions Inc. | Syringe-based microbubble generator |
CN111494741A (zh) * | 2020-05-25 | 2020-08-07 | 清华大学 | 一种用于体外循环的人工肺 |
Also Published As
Publication number | Publication date |
---|---|
EP2673039A4 (de) | 2018-03-07 |
EP2673039A1 (de) | 2013-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK170294B1 (da) | Indretning til cirkulation af blod uden for legemet ved kardiovaskulær assistance | |
CN101420993B (zh) | 用于血液回路的快速灌注连接器 | |
JPS5985666A (ja) | 血液貯蔵体 | |
CN115998976A (zh) | 双室气体交换器和用于呼吸支持的方法 | |
US8574309B2 (en) | Two-stage system and method for oxygenating and removing carbon dioxide from a physiological fluid | |
JP6234369B2 (ja) | ナノチューブと人工肺とを備えるガス交換装置 | |
US6723284B1 (en) | Membrane apparatus with enhanced mass transfer, heat transfer and pumping capabilities via active mixing | |
US20120289881A1 (en) | System and Implantable Device for Treating Chronic Kidney Disease | |
EP0226085A2 (de) | Herz-Lungen-Maschine zur Sauerstoffanreicherung des Blutes eines Patienten | |
WO2012108855A1 (en) | A two-stage system and method for oxygenating and removing carbon dioxide from a physiological fluid | |
CN111556766A (zh) | 模块化体外可移动式肺辅助装置 | |
Han et al. | Development of an ambulatory extracorporeal membrane oxygenation system: from concept to clinical use | |
US20200368420A1 (en) | Systems and methods for exchanging small molecules with fluid | |
US10251989B2 (en) | Compact pulmonary assist device for destination therapy | |
Jung et al. | Pulsatile versus nonpulsatile flow to maintain the equivalent coronary blood flow in the fibrillating heart | |
US20220273853A1 (en) | Arrangement for Transporting a Liquid Through a Cannula System, Corresponding Kit and Method | |
Kim et al. | STUDY ON THE DESIGNING OF THE INTRAVENOUS OXYGENATOR | |
Nishida et al. | An Oxygenator With a Built-in Hemoconcentrator In Vitro Performance and Pre Clinical In Vivo Assessment of the Final Prototype | |
Nakano et al. | Study on optimization of heat exchanger for oxygenator using multi-objective genetic algorithm (MOGA) | |
Lee et al. | Microchannel technologies for artificial lungs | |
Wang et al. | Compact OxyRVAD for two weeks total respiratory and right heart assistance | |
Oh et al. | IMMOBILIZATION AND ASSESSMENT OF CARBONIC ANHYDRASE ON HOLLOW FIBER MEMBRANES FOR ENZYME-ENHANCED ARTIFICIAL LUNGS | |
Cevallos et al. | Mortality benefit in LD100 Smoke/Burn Induced ARDS by AVCO2R in Sheep | |
Lande | SEQUENCED, HEMOGLOBIN BASED ARTIFICIAL GILLS,“SYNTHETIC GILL”, SUPPORTS DIVER’S OR CLIMBER’S BREATHING BY CONCENTRATING AND STORING O2 FROM SEAWATER OR THIN AIR AT ALTITUDE, AND BY DISPOSING OF CO2 | |
Lande | ARTIFICIAL GILL COMPLEMENTS LIQUID BREATHING FOR DIVING TO GREAT DEPTHS WITHOUT THE BENDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11858232 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011858232 Country of ref document: EP |